ACUS (Acusphere) ROIC %: -118.95% (As of Sep. 2008)


What is Acusphere ROIC %?

Acusphere ACUS -90.00% ROIC % is -118.95% as of Sep. 2008.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Acusphere's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2008 was -118.95%.

As of today (2026-06-27), Acusphere's WACC % is 0.00%. Acusphere's ROIC % is 0.00% (calculated using TTM income statement data). Acusphere earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Acusphere  (OTCPK:ACUS) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Acusphere's WACC % is 0.00%. Acusphere's ROIC % is 0.00% (calculated using TTM income statement data). Acusphere earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Acusphere ROIC % Related Terms


Acusphere ROIC % Historical Data

* Premium members only.

The historical data trend for Acusphere's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acusphere ROIC % Chart

Acusphere Annual Data
Trend Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
ROIC %
Get a 7-Day Free Trial -302.15 -256.13 -124.72 -118.99 -120.18

Acusphere Quarterly Data
Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -146.55 -132.17 -141.34 -118.84 -118.95

ACUS vs CNAB, PIRE, MJNE: ROIC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Acusphere's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acusphere ROIC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acusphere's ROIC % distribution charts can be found below:

* The bar in red indicates where Acusphere's ROIC % falls into.



Acusphere ROIC % Calculation

Acusphere's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2007 is calculated as:

ROIC % (A: Dec. 2007 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2006 ) + Invested Capital (A: Dec. 2007 ))/ count )
=-52.727 * ( 1 - % )/( (49.856 + 37.889)/ 2 )
=-52.727/43.8725
=-120.18 %

where

Acusphere's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2008 is calculated as:

ROIC % (Q: Sep. 2008 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2008 ) + Invested Capital (Q: Sep. 2008 ))/ count )
=-39.744 * ( 1 - % )/( (35.38 + 31.445)/ 2 )
=-39.744/33.4125
=-118.95 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2008) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -118.95% mean?
Acusphere (ACUS) has a ROIC % of -118.95% as of Sep. 2008. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Acusphere and its competitors.
Is Acusphere's ROIC % too high?
Acusphere's current ROIC % is -118.95%.
How does Acusphere's ROIC % compare to CNAB and PIRE?
Acusphere's ROIC % of -118.95% can be compared against companies in the Drug Manufacturers industry. The industry median ROIC % is 4.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Drug Manufacturers company?
The median ROIC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Acusphere and its competitors. For the Drug Manufacturers industry, the median ROIC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acusphere's current ROIC % is -118.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acusphere stock overvalued right now?
Acusphere (ACUS) has a current ROIC % of -118.95%. The current ROIC % is -118.95%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Acusphere (ACUS), the current ROIC % is -118.95% as of Sep. 2008. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acusphere Business Description

Address 99 Hayden Avenue, Suite 385, Lexington, MA, USA, 02421
Acusphere Inc is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology.